News

Vaccine candidate UB-311 is safe, well tolerated, and triggered an antibody response against beta-amyloid in 93% of patients with mild Alzheimer’s disease, according to now published data from a Phase 2a trial. Immunization also led to nonsignificant trends in reducing beta-amyloid and slowing cognitive, functional, and dementia decline,…

The PrecivityAD blood test from C2N Diagnostics significantly influences clinicians’ decisions about whether to treat people with cognitive impairments for Alzheimer’s disease. C2N, which sponsored the recent study, believes those findings offer robust real-world evidence that blood biomarker testing in the clinic helps to guide treatment decisions…

Quest Diagnostics has launched a consumer-initiated blood test for adults in the U.S. that assesses Alzheimer’s disease risk by measuring levels of certain forms of the amyloid beta protein, a known marker of the neurodegenerative disorder. Called AD-Detect, the test is now the first of its kind…

Racial and ethnic minority groups in the U.S. are underrepresented in Alzheimer’s disease neuroimaging research, but the gap may be starting to close, according to a review study. Efforts to address the issue in recent years have been associated with small increases in minority inclusion, but much work remains…

Eli Lilly’s anti-amyloid therapy donanemab significantly slowed cognitive decline for most people with early Alzheimer’s disease in the Phase 3 TRAILBLAZER-ALZ 2 clinical trial. The benefits were more pronounced among patients younger than 75 years and among those with mild cognitive impairment (MCI) relative to those with early…

Recruitment has begun for a Phase 2 clinical trial that’s evaluating Cognition Therapeutics’ once daily oral therapeutic candidate Elayta in adults with early Alzheimer’s disease. START (NCT05531656) expects to enroll about 540 adults, ages 50-85. The University of Kentucky Sanders-Brown Center on Aging (SBCoA) is the first to…

The U.S. Food and Drug Administration (FDA) has granted full approval to Eisai and Biogen’s Leqembi (lecanemab), the first treatment shown to slow disease progression in adults with early Alzheimer’s disease. Leqembi won accelerated (conditional) approval in January based on Phase 2 trial data that showed it…

On-demand treatment with BXCL501, an orally dissolving film formulation of dexmedetomidine, significantly eased episodes of agitation among Alzheimer’s disease patients in a Phase 3 clinical trial, according to topline results announced by the therapy’s developer, BioXcel Therapeutics. “We believe these results represent a significant milestone for BioXcel Therapeutics…

In the earliest stages of Alzheimer’s disease, even before cognitive symptoms have become apparent, there are detectable changes in the makeup of bacteria in the gut, a study shows. The finding suggests that analyses of gut bacteria may help identify early Alzheimer’s, according to researchers. “By the time…

A U.S. Food and Drug Administration (FDA) advisory committee has decided that data from the Phase 3 Clarity AD trial are sufficient to confirm the clinical benefits of Leqembi (lecanemab) for the treatment of early Alzheimer’s disease. The FDA now will consider the unanimous opinion of the committee…